Cassinello, JArranz, J ÁPiulats, J MSánchez, APérez-Valderrama, BMellado, BCliment, M ÁOlmos, DCarles, JLázaro, M2024-01-232024-01-232017-11-13http://hdl.handle.net/10668/11795http://hdl.handle.net/20.500.12105/17346Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.engVoRhttp://creativecommons.org/licenses/by/4.0/AbirateroneAndrogen deprivation treatmentCabazitaxelCastration-resistant prostate cancerDocetaxelEnzalutamideHormone-sensitive advanced prostate cancerRadium 223Antineoplastic AgentsHumansMaleProstatic NeoplasmsAttribution 4.0 International2913456220157-6810.1007/s12094-017-1783-21699-3055Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexicoopen access